Nureca Ltd. · NSE:NURECA
Nureca — Q2 FY2024 Earnings Presentation
30 slides from Nureca's earnings presentation, Nov 4, 2023
Slide 1: Letter to stock exchanges: Investor Presentation
NURECA - www.nureca.com Dated - 04.11.2023 BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA LIMITED Corporate Relations Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot no. C/1 Dalal Street, Fort G Block, Bandra Kurla Complex, Bandra (E) Mumbai-400001 Mumbai-400051
Slide 2: Q2 & H1 2024 Earnings Presentation
Q2 & H1 2024 Earnings Presentation www.nureca.com
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Our Vision
Our VISION To become one of the World’s most Respected Home Healthcare and wellness companies by empowering customers through innovative , accessible and data driven healthcare solutions.
Slide 5: Financial Performance Highlights for Q2 FY24
Financial Performance Highlights for Q2 FY24 Nureca is a debt-free, asset light company and has a healthy liquidity position. Results ₹ 436 Million ₹ 314 Million GMV Operating Revenue ₹ 46 Million ₹ 29 Million EBITDA Profit after Tax
Slide 6: 3 Established Brands
Chronic Diseases Nebulizer; BP Monitors; Finger Pulse Oximeter; Glucose meter; Thermometers, connected devices Are specialists in home Lifestyle & Fitness healthcare and wellness Humidifiers & Steamers; Personal Scales; Massagers; Yoga & Exercise; Fitness Tracking; Dental & Personal Care products Or
Slide 7: Q2 FY24 Financial Performance Highlights
Q2 FY24 Financial Performance Highlights 314 mn | (15)% 46 mn | 252% 29 mn | 200% Revenue | YoY Growth EBITDA | YoY Growth PAT | YoY Growth 300 mn | (8)% 96% Revenue contribution Online Sales Revenue | YoY Growth from Online Sales
Slide 8: H1 FY24 Financial Performance Highlights
H1 FY24 Financial Performance Highlights 526 mn | (16)% 44 mn | 157% 22mn | 131% Revenue | YoY Growth EBITDA | YoY Growth PAT | YoY Growth 3% 2% Return on Capital Employed Return on Equity
Slide 9: Strategic Pillars
Strategic Pillars 1 D2C growth Omnipresence Manufacturing Connected Health Expand our already strong Establish pan India sales Building a strong manufacturing Transform lives of our users presence online by network with expansive reach base in India with focus on quality, through our Connected healt
Slide 10: D2C: Our growing digital customer base
D2C Our growing digital customer base Our customer base has grown exceptionally over the last 5 years which is a result of remarkable quality of our 97% 1.29 cr 2 products that led to word-of-mouth marketing by our Revenue Contribution Happy Economic Times loyal customer base. Currently, our product
Slide 11: Strategic Pillars
Strategic Pillars D2C growth 2 Omnipresence Manufacturing Connected Health Expand our already strong Establish pan India sales Building a strong manufacturing Transform lives of our users presence online by network with expansive reach base in India with focus on quality, through our Connected healt
Slide 12: Omnipresence
Omnipresence We are expanding our strong portfolio of products by building a strong trade distribution network pan India and have onboarded 168 distributors till date. 12/28 27 7991+ 68 Live States Sales Team Retail Touchpoints Cities Strength Over the years, our brand, Dr Trust, has garnered substa
Slide 13: Strategic Pillars
Strategic Pillars D2C growth Omnipresence 3 Manufacturing Connected Health Expand our already strong Establish pan India sales Building a strong manufacturing Transform lives of our users presence online by network with expansive reach base in India with focus on quality, through our Connected healt
Slide 14: Manufacturing
Manufacturing Our wholly owned subsidiary Nureca Technologies, started manufacturing activity in April 2022 and has obtained ISO 13485:2016 and ISO 9001:2015 certifications from notified body Intertek, for Nebulizers and Blood pressure monitors. We have also received license for manufacturing Nebuli
Slide 15: Medical Products manufactured by Nureca Technologies
Medical Products manufactured by Nureca Technologies BP Monitors Nebulizers Thermometers Heat belts
Slide 16: Orthopedic Products for Tailbone support
Orthopedic Products for Tailbone support manufactured by Nureca Technologies Coccyx Pillows Knee Pillows Backrest Pillows
Slide 17: Orthopedic Products engineered for Better Sleep
Orthopedic Products engineered for Better Sleep manufactured by Nureca Technologies Memory Contoured Foam Pillow Cervical Pillow Cooling Gel Memory Foam Orthopedic Pillow Cervical Pillow
Slide 18: Mother & Baby Care products manufactured by Nureca Technologies
Mother & Baby Care products manufactured by Nureca Technologies Electric Breast Pump Manual Breast Pump ●USB Rechargeable Multi- ●Ergonomic Handle & Anti- Mode Technology Backflow System ●Customizable Intensity and ●Quiet Operation, Customize Massage Modes Suction and Speed ●Easy, Quiet, and Perfect
Slide 19: Strategic Pillars
Strategic Pillars D2C growth Omnipresence Manufacturing 4 Connected Health Expand our already strong Establish pan India sales Building a strong Transform lives of our users presence online by network with expansive reach manufacturing base with through our Connected innovating new products and deep
Slide 20: Connected Health
Connected Health Dr Trust 360 Our unified app to track all the health metrics and vitals collected from various Dr Trust devices. Users can share real time health data with doctors, fitness trainers and health guardians Progress so far - 11,73,131+ Users and counting
Slide 21: Q2 & H1 FY24 Consolidated Financial Update
Q2 & H1 FY24 CONSOLIDATED FINANCIAL UPDATE
Slide 22: Q2 FY24 Consolidated Financials
Q2 FY24 Consolidated Financials Revenue (Rs. Mns) GMV Growth (Rs. Mns) (15)% (13)%
Slide 23: Q2 FY24 Consolidated Financials
Q2 FY24 Consolidated Financials EBITDA (Rs. Mns) EBITDA Margin% PAT (Rs. Mns) PAT Margin% 252% 200% In Q2'FY24, provision of Rs. 9.7 Mn is made against Inventory and provision of Rs. 2.8 Mn is made against CSR assets.
Slide 24: H1 FY24 Consolidated Financials
H1 FY24 Consolidated Financials Revenue (Rs. Mns) GMV Growth (Rs. Mns) (13)% (16)%
Slide 25: H1 FY24 Consolidated Financials
H1 FY24 Consolidated Financials EBITDA (Rs. Mns) EBITDA Margin% PAT (Rs. Mns) PAT Margin% 157% 131% In H1'FY24, provision of Rs. 18.9 Mn is made against Inventory and provision of Rs. 2.8 Mn is made against CSR assets.
Slide 26: FCFO in H1 FY24
FCFO in H1 FY24 Net cash Closing Cash Opening Cash outflow as on 30th as on 1st April towards September 2023 financing 2023 activities Payment of lease liabilities (7) Others (1) Net cash outflow Net cash flow towards from investing operating activities activities Trading Cash Flow* (67) Operating c
Slide 27: Key Ratios
ROCE(%) ROE(%) Key Ratios EBITDA(%) PAT(%)
Slide 28: Key Ratios
Working Capital Turnover Employee Cost/Revenue (%) Key Ratios
Slide 29: Shareholder Information
Shareholder Information Nureca Limited listed on Stock Exchanges (BSE and NSE) in 2021 Shareholding as on 30th September 2023 NSE Ticker NURECA BSE Ticker 543264 IPO Listing Date 25th February 2021 Market Cap (INR Cr) 362 Share Price (INR) 361 Shares Outstanding 1,00,00,175 Industry Healthcare
Slide 30: Contact Us
Contact Us Investor Relations Gurvikram Singh cs@nurecacom Website Corporate: www.Nureca.com Ecom Store: www.drtrust.in Address Office No. 101, Udyog Bhavan, Sonawala Lane, Goregaon East, Mumbai, Maharashtra - 400063 THINK. FEEL. CREATE